Mometamax Ultra
Active substance
ATC code
Species
Dogs
Indications
Treatment of acute otitis externa and acute exacerbation of recurrent otitis externa caused by mixed infections of susceptible strains of bacteria sensitive to gentamicin (Staphylococcus pseudintermedius) and fungi sensitive to posaconazole (Malassezia pachydermatis).
Dose to be administered and administration route
Auricular use.
Single treatment.
The recommended dosage is a single dose of 0.8 ml per infected ear.
The maximum clinical response may not be seen until 28 days after administration.
Instructions for use:
Clean and dry the external ear canal before administering the product.
The product is preservative-free and should be handled using clean technique.
Before first use, shake the bottle vigorously for 15 seconds. Unwrap the syringe with the adapter attached. Remove the cap from the bottle and insert the syringe adapter by pressing it firmly into the top of the bottle using the attached syringe.
1. Invert the bottle and draw up 0.8 ml per ear.
2. Return the bottle to an upright position and remove the syringe from the adapter.
3. Leave the syringe adapter in place and replace the cap on the bottle.
4. Place the tip of the syringe at the entrance of external ear and administer the 0.8 ml dose. The applied dose will flow into the ear canal.
5. After application, the ear can be massaged gently to ensure distribution of the product throughout the ear canal.
Following dosing, the head should be restrained for approx. 2 minutes to prevent shaking and dislodging of product.
Use a new syringe for each infected ear. Shake the bottle vigorously for 15 seconds before use. Remove the cap. Insert the syringe tip into the adapter. Follow steps 1. to 5. of the dosing instructions.
Dosing syringes compatible with the syringe adapter are provided. Some commercially available syringes may not be compatible with the syringe adapter.
Do not clean the ear canal for at least 28 days after the administration to allow contact of the product with the ear canal.
Adverse reactions
No adverse reactions related to treatment were observed in clinical trials.